Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.

MLA

Vergès, Bruno, et al. “Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 38, no. 9, Sept. 2018, pp. 2198–206. EBSCOhost, https://doi.org/10.1161/ATVBAHA.118.310990.

APA

Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Sberna, A.-L., Petit, J.-M., Degrace, P., & Demizieux, L. (2018). Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(9), 2198–2206. https://doi.org/10.1161/ATVBAHA.118.310990

Chicago

Vergès, Bruno, Laurence Duvillard, Jean Paul Pais de Barros, Benjamin Bouillet, Sabine Baillot-Rudoni, Alexia Rouland, Anne-Laure Sberna, Jean-Michel Petit, Pascal Degrace, and Laurent Demizieux. 2018. “Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.” Arteriosclerosis, Thrombosis, and Vascular Biology 38 (9): 2198–2206. doi:10.1161/ATVBAHA.118.310990.